Company: STAA
Filing Date: 2025-10-06
Form Type: DEFA14A
Source: 0001193125-25-230935
Chunk: 2

Company: STAAR SURGICAL CO
Filing Date: 2025-10-06
Form: DEFA14A
Chunk 2
---
 STAAR has received no acquisition proposals in the last decade or more. |

| • |     | Despite media reports of takeover interest in STAAR in July 2024, STAAR received no acquisition proposal from 
 anyone other than Alcon.                                                                                      |

| • |     | Despite Broadwood’s public statement that there were “several credible parties” and                                                          
 Broadwood’s efforts to find buyers, Broadwood has not delivered, and STAAR has not received, any acquisition proposal other than from Alcon. |

| 2. | Broadwood allegation: “Management projections were revised downward at the last minute to cast a more 
 pessimistic outlook on the business”                                                                  |

| • |     | STAAR Response – Broadwood is twisting the truth on STAAR’s financial projections |

| • |     | Management presented optimistic projections to Alcon to extract the highest possible value in the negotiation, 
 which is in the best interests of STAAR stockholders.                                                          |

| • |     | Sharing more bullish projections with a buyer is a standard practice in the context of a sale negotiation, and it 
 fully aligns with the objective of maximizing value for stockholders.                                             |

| • |     | Management also prepared projections that reflected a modestly lower view of the future growth profile of STAAR, 
 which was approved by the STAAR Board for use in the fairness opinion prepared by the Board’s financial advisor. |

| • |     | The projections for the fairness opinion reflect management’s best expectation for future growth. However,          
 those projections do not fully reflect the potential impact of risks and headwinds, which are difficult to measure. |

| 3. | Broadwood allegation: “Numerous business entanglements and management’s financial 
 interests” influenced the decision to sell                                        |

| • |     | STAAR Response – Broadwood is creating a false narrative by questioning the Board’s 
 independence                                                                        |

| • |     | The Chair of the STAAR Board is a highly regarded ophthalmic surgeon, was formerly the President of the American                                                                                                                                
 Society of Cataract and Refractive Surgery and is well known to most major ophthalmic industry participants. Her extensive knowledge of the ophthalmic industry and its participants, together with her experience as a consultant for numerous 
 ophthalmic companies, including prior consulting work with Alcon, enhances her effectiveness as a director and does not impair her independence and objectivity.                                                                                |

| • |     | Broadwood’s perceived entanglements of former Board